AZOPT: Uses, Dosage & Side Effects
Carbonic Anhydrase Inhibitor — Lowers intraocular pressure in glaucoma
Quick Facts About AZOPT
Key Takeaways About AZOPT
- Effective IOP reduction: AZOPT lowers intraocular pressure by inhibiting carbonic anhydrase II in the ciliary body, reducing aqueous humor production by approximately 15–20%, and typically lowering IOP by 3–5 mmHg
- Twice-daily dosing: The standard dose is one drop in the affected eye(s) twice daily, morning and evening. Always shake the bottle well before use as AZOPT is a suspension
- Sulfonamide allergy warning: AZOPT belongs to the sulfonamide class. Do not use if you are allergic to sulfonamide drugs, as cross-reactivity can occur with medications used for diabetes, infections, and diuretics
- Contact lens precaution: Remove soft contact lenses before applying AZOPT and wait at least 15 minutes before reinserting them, as the preservative benzalkonium chloride can be absorbed by and discolor soft lenses
- Serious skin reactions: Although rare, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Stop using AZOPT and seek medical attention immediately if you develop a rash, blistering, or mouth sores
What Is AZOPT and What Is It Used For?
AZOPT contains brinzolamide, a carbonic anhydrase inhibitor that lowers intraocular pressure (IOP) in the eye. It is prescribed to treat elevated IOP in patients with open-angle glaucoma or ocular hypertension, conditions that, if left untreated, can damage the optic nerve and lead to permanent vision loss.
AZOPT belongs to a group of medications called carbonic anhydrase inhibitors (CAIs). Carbonic anhydrase is an enzyme found throughout the body, but in the eye, the isoform carbonic anhydrase II (CA-II) plays a critical role in the ciliary processes, where aqueous humor is produced. Aqueous humor is the clear fluid that fills the front chamber of the eye, nourishing the lens and cornea while maintaining the eye's shape and internal pressure. Under normal conditions, aqueous humor is continuously produced and drained in a balanced cycle that maintains stable intraocular pressure.
In conditions such as open-angle glaucoma and ocular hypertension, this balance is disrupted, typically because of impaired drainage through the trabecular meshwork. The resulting buildup of aqueous humor increases intraocular pressure, which over time can compress and damage the optic nerve fibers at the back of the eye. This progressive damage leads to gradual peripheral vision loss that, if untreated, can advance to tunnel vision and eventually total blindness. Glaucoma is one of the leading causes of irreversible blindness worldwide, affecting an estimated 80 million people globally.
By inhibiting CA-II in the ciliary processes, AZOPT reduces the formation of bicarbonate ions, which in turn decreases sodium and fluid transport into the posterior chamber of the eye. This results in a measurable reduction in aqueous humor production, typically lowering IOP by approximately 3–5 mmHg from baseline. Clinical trials have demonstrated that brinzolamide administered twice daily produces consistent IOP reductions throughout the day, making it a reliable choice for long-term glaucoma management.
AZOPT may be used alone (monotherapy) when beta-blocker eye drops are contraindicated or insufficient, or it may be combined with other IOP-lowering medications. It is commonly used alongside prostaglandin analogs (such as latanoprost or travoprost) or beta-blockers (such as timolol). A fixed-dose combination product containing brinzolamide and timolol (marketed as AZARGA) is also available for patients who require both agents.
Brinzolamide is a potent and selective inhibitor of carbonic anhydrase isoenzyme II (CA-II). In the ciliary processes of the eye, CA-II catalyzes the reversible hydration of carbon dioxide to form bicarbonate and hydrogen ions. This reaction is essential for the secretion of aqueous humor. By blocking CA-II, brinzolamide reduces the rate of aqueous humor formation, leading to a decrease in intraocular pressure. Unlike oral carbonic anhydrase inhibitors such as acetazolamide, topical brinzolamide achieves therapeutic concentrations locally in the eye with minimal systemic absorption, resulting in fewer systemic side effects.
What Should You Know Before Using AZOPT?
Before using AZOPT, you should be aware of several important contraindications, warnings, and precautions. AZOPT is a sulfonamide derivative, and patients allergic to sulfonamides should not use it. It is also contraindicated in patients with severe kidney impairment or hyperchloremic acidosis. Inform your doctor about all medications you are taking and any existing medical conditions.
While AZOPT is generally well-tolerated as a topical ophthalmic preparation, there are important medical considerations that must be evaluated before initiating treatment. Because brinzolamide is a sulfonamide, it shares potential cross-reactivity with other sulfonamide-containing medications. Additionally, although systemic absorption after topical ocular administration is low, some of the active substance does enter the bloodstream and is eliminated primarily through the kidneys.
Contraindications
You should not use AZOPT if:
- Severe kidney impairment: Since brinzolamide and its metabolites are eliminated primarily through the kidneys, AZOPT is contraindicated in patients with severe renal impairment (creatinine clearance below 30 ml/min). Accumulation of the drug could increase the risk of systemic side effects.
- Allergy to brinzolamide or any ingredient: If you have a known hypersensitivity to brinzolamide or any of the excipients in AZOPT (including benzalkonium chloride), you must not use this medication.
- Sulfonamide allergy: AZOPT is a sulfonamide derivative. If you are allergic to sulfonamide drugs, including those used to treat bacterial infections, diabetes (e.g., sulfonylureas), or as diuretics (e.g., hydrochlorothiazide), you may experience a cross-allergic reaction to AZOPT. The same types of allergic reactions that occur with systemic sulfonamides, including severe skin reactions and blood disorders, have been observed with topical sulfonamides.
- Hyperchloremic acidosis: AZOPT should not be used if you have hyperchloremic acidosis, a condition characterized by excessive acidity in the blood. Carbonic anhydrase inhibition can worsen metabolic acidosis.
Warnings and Precautions
Speak with your healthcare provider before using AZOPT if any of the following apply to you:
- Reddish, non-raised, target-like or circular patches on the trunk, often with central blisters, skin peeling
- Ulcers in the mouth, throat, nose, genitals, or eyes
- Fever and flu-like symptoms preceding a widespread rash
- These may be signs of Stevens-Johnson syndrome or toxic epidermal necrolysis, which are potentially life-threatening
- Kidney or liver problems: Even mild to moderate kidney or liver impairment may require closer monitoring. Your doctor may need to adjust treatment or perform additional blood tests to assess organ function during therapy.
- Dry eyes or conjunctival problems: AZOPT contains benzalkonium chloride, a preservative that can exacerbate dry eye symptoms and cause irritation of the conjunctiva. Patients with pre-existing dry eye disease or conjunctival disorders should discuss preservative-free alternatives with their ophthalmologist.
- Concurrent sulfonamide use: If you are taking other sulfonamide medications, inform your doctor. The combination may increase the risk of systemic sulfonamide-related adverse effects, including blood disorders and metabolic disturbances.
- Pseudoexfoliative or pigmentary glaucoma: Although AZOPT can be used in these subtypes of open-angle glaucoma, your ophthalmologist may monitor you more closely, as these conditions may respond differently to IOP-lowering therapy.
- Narrow-angle (angle-closure) glaucoma: AZOPT has not been studied extensively in patients with angle-closure glaucoma, where IOP can rise rapidly due to anatomical blockage of aqueous humor drainage. This condition typically requires different treatment approaches, including laser iridotomy or surgical intervention.
Pregnancy and Breastfeeding
AZOPT is not recommended during pregnancy unless clearly necessary and prescribed by your doctor. There are limited data from the use of brinzolamide in pregnant women. Animal reproductive toxicity studies at doses significantly exceeding human ophthalmic exposure showed developmental abnormalities in offspring, although the relevance of these findings to human use at therapeutic doses is uncertain.
Women of childbearing potential should use effective contraception during treatment with AZOPT. If you become pregnant while using AZOPT, contact your healthcare provider immediately to discuss whether to continue treatment. The decision to use AZOPT during pregnancy must weigh the potential risk to the fetus against the need to preserve the mother's vision.
It is not known whether brinzolamide is excreted in human breast milk. Given the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother. Consult your healthcare provider for personalized advice.
Driving and Operating Machinery
AZOPT can cause temporary blurred vision and other visual disturbances after instillation. Do not drive or operate machinery until your vision has cleared. The medication may also cause dizziness and drowsiness in some patients, which could impair the ability to perform tasks requiring mental alertness and physical coordination. If you experience these effects, refrain from driving until they have resolved.
Important Information About Benzalkonium Chloride
AZOPT contains benzalkonium chloride as a preservative. This substance can cause eye irritation, particularly with prolonged use, and is known to discolor soft contact lenses. If you wear contact lenses, you must remove them before applying AZOPT and wait at least 15 minutes after instillation before reinserting them. Patients who use preservative-free artificial tears alongside AZOPT should discuss the optimal timing of administration with their ophthalmologist.
How Does AZOPT Interact with Other Drugs?
AZOPT can interact with other carbonic anhydrase inhibitors and certain medications that affect acid-base balance or kidney function. The most important interaction is with other carbonic anhydrase inhibitors (acetazolamide, dorzolamide), which should not be used concurrently. Always inform your doctor about all medications you are taking, including other eye drops.
Drug interactions with AZOPT primarily arise from its mechanism as a carbonic anhydrase inhibitor and its sulfonamide chemical structure. Although topical ocular administration results in much lower systemic exposure compared to oral carbonic anhydrase inhibitors, some brinzolamide does enter the bloodstream and can interact with other medications. Understanding these interactions is essential for safe use.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustments or avoidance of concurrent use:
| Drug | Interaction | Clinical Significance |
|---|---|---|
| Acetazolamide (oral) | Additive carbonic anhydrase inhibition increases risk of systemic side effects | Avoid combination — increased risk of metabolic acidosis and electrolyte imbalances |
| Dorzolamide (eye drops) | Both are topical carbonic anhydrase inhibitors with overlapping mechanisms | Do not use together — no additive benefit, increased adverse effects |
| High-dose salicylates (aspirin >2 g/day) | Carbonic anhydrase inhibitors may enhance salicylate toxicity in acidotic patients | Use with caution — monitor for signs of salicylate toxicity |
Other Notable Interactions
The following interactions require awareness. Your doctor should be informed if you are taking any of these medications:
| Drug | Effect | Action Required |
|---|---|---|
| Timolol (eye drops) | Additive IOP-lowering effect; well-studied combination | Safe combination; wait 5 minutes between drops |
| Prostaglandin analogs (latanoprost, travoprost) | Additive IOP-lowering effect through different mechanisms | Safe combination; wait 5 minutes between drops |
| Topiramate | Both inhibit carbonic anhydrase; potential additive metabolic acidosis | Monitor for signs of metabolic acidosis |
| Metformin | Theoretical increased risk of lactic acidosis if metabolic acidosis develops | Monitor kidney function and acid-base balance |
| Other eye drops | May dilute or wash out AZOPT if applied too closely together | Wait at least 5 minutes between different eye drops; apply eye ointments last |
Many glaucoma patients use two or more different eye drops. To ensure each medication is properly absorbed, wait at least 5 minutes between applying different eye drops. Apply eye ointments after all eye drops. If AZOPT is used with other eye drops, apply AZOPT first (or as directed by your ophthalmologist), as its suspension formulation may temporarily blur vision.
What Is the Correct Dosage of AZOPT?
The recommended dose of AZOPT is one drop in the affected eye(s) twice daily, morning and evening. Always shake the bottle well before use, as AZOPT is a suspension. Apply the drops exactly as prescribed by your ophthalmologist and continue treatment for as long as directed to maintain effective intraocular pressure control.
AZOPT dosing is straightforward, as it is available in a single concentration (10 mg/ml brinzolamide suspension). The following guidelines represent standard dosing recommendations. Your ophthalmologist may adjust your treatment based on your individual response and IOP measurements.
Adults
Standard Adult Dosing
- Dose: 1 drop in the affected eye(s)
- Frequency: Twice daily (morning and evening), approximately 12 hours apart
- Duration: As long as prescribed by your ophthalmologist; glaucoma treatment is typically lifelong
- Single or both eyes: Use in both eyes only if your doctor has specifically prescribed this
Children and Adolescents
AZOPT is not recommended for use in infants, children, or adolescents under 18 years of age unless specifically prescribed by a specialist ophthalmologist. The safety and efficacy of brinzolamide have not been adequately established in the pediatric population. Childhood glaucoma is a specialized condition that requires management by a pediatric ophthalmologist who can determine the most appropriate treatment approach.
Elderly Patients
No dose adjustment is required for elderly patients. Clinical studies have included patients across a wide age range, and brinzolamide is generally well-tolerated in older adults. However, elderly patients may have reduced kidney function, which should be assessed before starting treatment. Your ophthalmologist will determine whether AZOPT is appropriate based on your overall health profile.
How to Apply AZOPT Correctly
Proper administration technique is essential for maximizing the effectiveness of AZOPT and minimizing side effects:
- Shake the bottle: AZOPT is a suspension (milky-white liquid). Shake the bottle well before each use to ensure the medication is evenly distributed.
- Wash your hands: Thoroughly wash your hands with soap and water before handling the bottle.
- Remove the cap: Unscrew the cap. If the safety collar is loose after removing the cap, remove it before using the product.
- Position the bottle: Hold the bottle upside down between your thumb and middle finger.
- Tilt your head back: Tilt your head back and pull down your lower eyelid with a clean finger to create a small pocket between the eyelid and the eye.
- Instill one drop: Bring the bottle tip close to your eye and gently press the bottom of the bottle with your index finger to release one drop. Use a mirror if it helps. Do not touch the dropper tip to your eye, eyelid, or any surface, as this can contaminate the drops.
- Apply nasolacrimal occlusion: After instilling the drop, close your eye and press gently with a finger on the inner corner of your eye (near the nose) for at least 1 minute. This technique, known as nasolacrimal occlusion, reduces systemic absorption by preventing the medication from draining through the nasolacrimal duct into the nose and throat.
- Repeat if needed: If your doctor has prescribed drops for both eyes, repeat the procedure for the other eye.
- Replace the cap: Screw the cap back on tightly immediately after use.
Finish one bottle before opening the next. If the drop misses your eye, try again.
Missed Dose
If you forget to apply a dose of AZOPT, use it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your regular routine. Do not apply a double dose to compensate for a missed one. Maintaining a consistent dosing schedule is important for optimal IOP control.
Overdose
If too much AZOPT is accidentally applied to the eyes, rinse the eyes with lukewarm water. Do not apply additional drops until it is time for your next regular dose. In the unlikely event of accidental oral ingestion, symptoms may include electrolyte imbalances, metabolic acidosis, and central nervous system effects. Contact your local poison control center or seek emergency medical attention. Treatment is supportive and symptomatic, as there is no specific antidote for brinzolamide.
If you stop using AZOPT without medical advice, the pressure in your eye will no longer be controlled, which can lead to progressive optic nerve damage and irreversible vision loss. Glaucoma often has no symptoms until significant damage has occurred, so it is essential to continue treatment even if you feel well.
What Are the Side Effects of AZOPT?
Like all medications, AZOPT can cause side effects, although not everyone experiences them. The most common side effects are blurred vision, eye irritation, eye pain, discharge from the eye, and a bitter or unusual taste in the mouth. Serious side effects are rare but include severe skin reactions such as Stevens-Johnson syndrome. Seek immediate medical attention if you develop blistering skin, mouth sores, or widespread rash.
The following side effects have been reported in clinical studies and post-marketing surveillance with AZOPT. Most side effects are mild to moderate and typically resolve with continued use or after discontinuation. However, some rare effects can be serious and require immediate medical attention.
- Reddish, non-raised, target-like or circular patches on the trunk, often with central blisters
- Skin peeling, ulcers in the mouth, throat, nose, genitals, or eyes
- These may be preceded by fever and flu-like symptoms
- These are signs of potentially life-threatening Stevens-Johnson syndrome or toxic epidermal necrolysis
Common Side Effects
- Blurred vision
- Eye irritation
- Eye pain
- Discharge from the eye
- Itchy eyes
- Dry eyes
- Abnormal sensation in the eye (foreign body feeling)
- Red eyes (ocular hyperemia)
- Unpleasant or bitter taste in the mouth (dysgeusia)
Uncommon Side Effects
- Eye effects: Sensitivity to light, conjunctival inflammation or infection, eyelid swelling, itching or redness of the eyelids, deposits in the eye, glare, burning sensation, eye surface growth (pterygium), increased eye pigmentation, tired eyes, eyelid crusting, increased tear production
- Heart/circulation: Reduced or impaired heart function, forceful/rapid/irregular heartbeat, decreased heart rate
- Respiratory: Difficulty breathing, shortness of breath, cough, sinus infection, sore throat, throat irritation, chest tightness, nosebleed, runny or stuffy nose, sneezing
- Nervous system: Dizziness, memory difficulties, depression, nervousness, emotional indifference, nightmares, general weakness, abnormal sensation, movement disorders, decreased libido
- Gastrointestinal: Abdominal pain, nausea, vomiting, upset stomach, frequent bowel movements, diarrhea, flatulence, indigestion, dry mouth, abnormal taste in the mouth, esophageal inflammation
- Other: Fatigue, kidney pain, muscle pain, muscle spasm, back pain, rash, itching, skin tingling, skin tightness, headache, decreased red blood cell count, increased blood chloride levels
Rare Side Effects
- Eye effects: Corneal swelling, double vision or decreased vision, abnormal vision, light flashes in the visual field, decreased eye sensitivity, swelling around the eye, increased intraocular pressure, optic nerve damage
- Other: Impaired memory, drowsiness, chest pain, nasal congestion, dry nose, tinnitus (ringing in the ears), hair loss, generalized itching, nervousness, irritability, irregular heartbeat, weakness, insomnia, wheezing
Frequency Not Known
- Eye effects: Abnormal eyelids, visual disturbances, corneal disease, eye allergy, poor eyelash growth or eyelash loss, eyelid redness
- Skin: Stevens-Johnson syndrome, toxic epidermal necrolysis (potentially life-threatening), skin redness, inflammation
- Other: Increased allergic symptoms, decreased sensation, tremor, loss of or reduced taste, decreased blood pressure, increased blood pressure, increased heart rate, joint pain, asthma, limb pain, abnormal liver function tests, swelling in arms or legs, frequent urination, decreased appetite, malaise
If you experience any side effects, including those not listed above, report them to your healthcare provider. You can also report side effects directly to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union). Reporting helps ensure the ongoing safety monitoring of medications.
How Should You Store AZOPT?
Store AZOPT at room temperature with no special storage conditions required. Keep out of reach of children. Once opened, discard the bottle after 4 weeks to protect against microbial contamination. Do not use after the expiration date printed on the packaging.
Proper storage of AZOPT ensures the medication remains sterile and effective throughout its shelf life. As an ophthalmic suspension, maintaining product integrity is particularly important for eye safety.
- Temperature: No special storage temperature requirements. Store at room temperature.
- After opening: You must discard the bottle 4 weeks after opening, even if solution remains. This is because the preservative benzalkonium chloride may not prevent microbial contamination beyond this period. Write the date of opening on the bottle or carton to keep track.
- Before opening: Use before the expiration date (marked as “EXP”) on the bottle and carton. The expiration date refers to the last day of the indicated month.
- Children: Keep out of sight and reach of children.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused medications to a pharmacy for proper disposal to help protect the environment.
What Does AZOPT Contain?
AZOPT contains brinzolamide 10 mg/ml as the active substance, meaning each milliliter of the suspension contains 10 mg of brinzolamide. The formulation also includes several inactive ingredients (excipients) that maintain the stability, sterility, and comfort of the eye drop suspension.
Understanding the composition of your medication can help identify potential allergens or sensitivities. The excipients play important roles in maintaining the physical and chemical properties of the eye drop suspension.
Active Ingredient
The active substance is brinzolamide at a concentration of 10 mg/ml. One milliliter of the suspension contains 10 mg of brinzolamide, a sulfonamide carbonic anhydrase inhibitor.
Inactive Ingredients (Excipients)
The other ingredients in AZOPT include:
- Benzalkonium chloride: Preservative (may cause eye irritation and discolor soft contact lenses)
- Carbomer 974P: Viscosity-enhancing agent that helps the suspension remain in contact with the eye surface
- Disodium edetate: Chelating agent that enhances the preservative effectiveness
- Mannitol (E421): Tonicity-adjusting agent
- Purified water: Solvent
- Sodium chloride: Tonicity-adjusting agent
- Tyloxapol: Surfactant that helps maintain the suspension
- Hydrochloric acid / Sodium hydroxide: Used in small amounts to adjust pH to physiological levels
Appearance and Pack Sizes
AZOPT is a milky-white (opaque) suspension supplied in plastic drop-tip bottles. It is available in pack sizes of 5 ml, 10 ml, or a triple pack containing three 5 ml bottles. Not all pack sizes may be marketed in every country. The drop-tip bottle is designed so that a gentle press on the bottom releases one drop at a time.
Frequently Asked Questions About AZOPT
Medical References
All medical information in this article is based on peer-reviewed research, international clinical guidelines, and official drug regulatory documentation. Evidence level: 1A (systematic reviews and meta-analyses of randomized controlled trials).
- European Medicines Agency (EMA). “AZOPT — Summary of Product Characteristics.” EMA EPAR Official European regulatory documentation for brinzolamide (AZOPT).
- U.S. Food and Drug Administration (FDA). “AZOPT — Prescribing Information.” FDA FDA-approved labeling and safety information for brinzolamide ophthalmic suspension.
- European Glaucoma Society (EGS) (2020). “Terminology and Guidelines for Glaucoma — 5th Edition.” EGS Guidelines Comprehensive European guidelines on glaucoma diagnosis and management.
- British National Formulary (BNF). “Brinzolamide: Indications, dose, contraindications, side effects, interactions.” BNF / NICE Comprehensive UK drug monograph including dosing and interaction data.
- Iester M. (2008). “Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension.” Clinical Ophthalmology. 2(3):517–523. doi:10.2147/opth.s3182 Peer-reviewed review of brinzolamide pharmacology and clinical efficacy.
- Tham YC, et al. (2014). “Global prevalence of glaucoma and projections of glaucoma burden through 2040.” Ophthalmology. 121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013 Landmark study on global glaucoma prevalence and public health impact.
- World Health Organization (WHO) (2023). “World Report on Vision.” WHO Vision Report WHO report on global vision impairment including glaucoma as a leading cause of blindness.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Medical Editorial Team
Specialists in ophthalmology, pharmacology, and clinical medicine
Our Editorial Team
iMedic's medical content is produced by a team of licensed specialist physicians and medical experts with solid academic backgrounds and clinical experience. Our editorial team includes:
Ophthalmology Specialists
Licensed physicians specializing in ophthalmology with documented experience in glaucoma management and ocular pharmacology.
Clinical Pharmacologists
Experts in clinical pharmacology with extensive knowledge of drug interactions, pharmacokinetics, and evidence-based prescribing.
Researchers
Academic researchers with published peer-reviewed articles on glaucoma treatment and carbonic anhydrase inhibitors.
Medical Review
Independent review panel that verifies all content against international medical guidelines and current research.
Qualifications and Credentials
- Licensed specialist physicians with international specialist competence
- Documented research background with publications in peer-reviewed journals
- Continuous education according to WHO, EMA, and international medical guidelines
- Follows the GRADE framework for evidence-based medicine
- No conflicts of interest or pharmaceutical industry funding
Transparency: Our team works according to strict editorial standards and follows international guidelines for medical information. All content undergoes multiple peer reviews before publication.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in ophthalmology, pharmacology, internal medicine, and clinical research.